Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities
Bronwen E. Shaw(Royal Marsden NHS Foundation Trust), F. Javier Bolaños-Meade, Voravit Ratanatharathorn(University of Michigan–Ann Arbor), Steven M. Devine(National Marrow Donor Program), Maxim Norkin(Centre Hospitalier Universitaire Vaudois), John M. McCarty(Virginia Commonwealth University), Leo Luznik(Johns Hopkins University), Farhad Khimani(Moffitt Cancer Center), Nosha Farhadfar(University of Florida Health), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hannah Choe(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alisha Mussetter(National Marrow Donor Program), Alan Howard(National Marrow Donor Program), Krishna V. Komanduri(University of Miami), Claudio Anasetti(Moffitt Cancer Center), Brian C. Shaffer(Memorial Sloan Kettering Cancer Center), Richard F. Ambinder(Johns Hopkins University), Nancy M. Hardy(University of Maryland, Baltimore), Antonio Martin Jimenez-Jimenez(Sylvester Comprehensive Cancer Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Linda J. Burns(University of Minnesota System), Nirav N. Shah(Medical College of Wisconsin), Mary M. Horowitz(Medical College of Wisconsin), Joseph A. Pidala(Moffitt Cancer Center), Asif Alavi(Wayne State University), Dennis L. Confer(National Marrow Donor Program), Katarzyna Jamieson(University of North Carolina at Chapel Hill), Xiaoying Tang(Beijing Institute of Technology)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k